2）Barker DJ. The origins of the developmental origins 3）American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics and the Society forMaternal-FetalMedicin. ACOG Practice Bulletin No. 204: Fetal Growth Restriction. Obstet Gynecol 2019; 133(2): e97-e109. 4））ACOG Practice Bulletin No. 107: Induction of labor. 6）Sakamoto M, Osato K, Kubo M, Nii M, Tanaka H, Murabayashi N, et al. Early-onset fetal growth restriction treated with the long-acting phosphodiesterase-5 inhibitor tadalafil: a case report. J Med Case Rep 2016; 10(1): 317.7）Kubo M, Umekawa T, Maekawa Y, Tanaka H, Nii M, Murabayashi N, et al. Retrospective study of tadalafil for fetal growth restriction: Impact on maternal and perinatal outcomes. J Obstet Gynaecol Res 2017; 43(2): 291-7.8）Kubo M, Tanaka H, Maki S, Nii M, Murabayashi N, Osato K, et al. Safety and dose-finding trial of tadalafil administered for fetal growth restriction; A phase-1 clinical study. J Obstet Gynaecol Res 2017; 43(7): 1159–68.9）Yoshikawa K, Umekawa T, Maki S, Kubo M, Nii M, Tanaka K, et al. Tadalafil improves L-NG-nitroarginine methyl ester-induced preeclampsia with fetal growth restriction-like symptoms in pregnant mice. Am J Hypertens 2017; 31(1): 89-96.1）Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. J Hum Hypertens 2017; 31(12): 782-6. theory. J Intern Med 2007; 261(5): 412-7.Obstet Gynecol 2009; 114(2p+1): 386-97.5）Tanaka H, Kubo M, Nii M, Maki S, Umekawa T, Ikeda T, et al. Treatment using tadalafil for severe pre-eclampsia with fetal growth restriction. J Obstet Gynaecol Res 2017; 43(7): 1205-8. 10）Tanaka K, Tanaka H, Maki S, Kubo M, Nii M, Magawa S, et al. Cardiac function and tadalafil used for treating fetal growth restriction in pregnant women without cardiovascular disease. J Matern Fetal Neonatal Med 2019; 32(15): 2460-2.11）Tanaka H, Maki S, Kubo M, Yuasa H, Umekawa T, Ikeda T. Treatment using tadalafil for dichorionic diamniotic twin pregnancy with fetal growth restriction. Clin Exp Obstet Gynecol 2018; 45(4): 591-3.12）Kubo-Kaneda M, Tanaka H, Maki S, Nii M, Umekawa T, Osato K, et al. Placental growth factor as a predictor of the efficacy of tadalafil treatment for fetal growth restriction. J Matern Fetal Neonatal Med 2019; 32(17): 2879-82.13）Tanaka H, Furuhashi FH, Toriyabe K, Matsumoto T, Magawa S, Nii M, et al. Management of fetal growth restriction using the contraction stress test: a case-control study. J Matern Fetal Neonatal Med 2019; 32(19): 3221-5.14）Furuhashi FH, Tanaka H, Kaneda MK, Maki S, Nii M, Umekawa T, et al. Safety trial of tadalafil administered for the treatment of preeclampsia. J Matern Fetal Neonatal Med 2020; 33(1): 167-70.15）Maki S, Tanaka H, Takakura S, Nii M, Tanaka K, Ogura T, et al. Tadalafil treatment for fetuses with early-onset growth restriction: a protocol for a multicentre, randomised, placebo-controlled, double-blind phase Ⅱ trial (TADAFERⅡb). BMJ Open 2022; 12(6): e054925.16）Groom KM, Ganzevoort W, Alfirevic Z, Papageorghiou AT, STRIDER Consortium Clinicians should stop prescribing sildenafil for fetal growth restriction (FGR): comment from the STRIDER Consortium. Ultrasound Obstet Gynecol 2018; 52(3): 295-6.17）Tachibana R, Umekawa T, Yoshikawa K, Owa T, Magawa S, Furuhashi F, et al. Tadalafil treatment in mice for preeclampsia with fetal growth restriction has neuro-benefic effects in offspring through modulating prenatal hypoxic conditions. Sci Rep 2019; 9(1): 234. 18）Maki S, Tanaka H, Tsuji M, Furuhashi F, Magawa S, Kaneda MK, et al. Safety evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth restriction (TADAFER): results from the phaseⅡtrial. J Clin Med 2019; 8(6): 856. 91文 献
元のページ ../index.html#105